NCT07365319
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07365319
Title A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer. (TeLuRide-008)
Acronym TeLuRide-008
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Eikon Therapeutics
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
NYU Langone Hospital Long Island RECRUITING Mineola New York 11501 United States Details
NYU Langone Hospital Manhattan RECRUITING New York New York 10016 United States Details
White Plains Hospital RECRUITING White Plains New York 10601 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field